Business Wire

Decagon Announces Commercial Pilot with Deutsche Telekom and Strategic Investment from T.Capital to Fuel Enterprise Growth

10.11.2025 16:00:00 CET | Business Wire | Press Release

Share

WEB SUMMIT 2025 – Decagon, the leader in conversational AI agents for concierge customer experiences, today announced a commercial pilot with global telecommunications provider Deutsche Telekom, as well as a strategic investment from T.Capital, the corporate venture arm of Deutsche Telekom.

Deutsche Telekom is the world’s largest telecommunications provider by revenue and serves hundreds of millions of mobile customers across the globe. T.Capital provides early- and late-stage strategic capital to companies that have synergies with parent Deutsche Telekom.

“Decagon’s powerful AI is helping businesses deliver an exceptional customer experience,” said Jonathan Abrahamson, Chief Product & Digital Officer at Deutsche Telekom. “The company's innovative approach fits perfectly to our own vision to elevate customer experiences through technology, and we look forward to both our commercial pilot and joining the roster of top-flight investors fueling the company’s impressive product velocity and enterprise growth trajectory.”

“Deutsche Telekom helps millions of people connect with each other in meaningful ways, every single day. We’re proud to play a part in helping them do just that, and we are excited for the holistic partnership with T.Capital as we continue scaling our enterprise operations,” said Jesse Zhang, co-founder and CEO of Decagon.

The announcement was made as Web Summit 2025 kicks off in Lisbon, where Decagon co-founder and CEO Jesse Zhang will give marquee talks about how Decagon is quickly empowering many of the world’s most respected enterprise companies to build, optimize, and scale AI agents that work seamlessly across chat, email, and voice to deliver the always-on concierge experiences customers deserve. Attendees can find him on both the AI Summit Stage and Centre Stage:

  • Tuesday, November 12 @ 3:55pm GMT | AI Summit Stage
    Closing keynote: Decagon is winning the enterprise–here's how
  • Wednesday, November 13 @ 12:40pm GMT | Centre Stage
    Panel: From demos to deployment: The enterprise AI journey

About Decagon
Decagon empowers the world’s leading enterprise companies to build, optimize, and scale AI agents that give customers the always-on concierge experiences they deserve. Founded in 2023 and launched in the summer of 2024, Decagon is based in San Francisco, with offices in New York City and London. For more information, visit www.decagon.ai.

About Deutsche Telekom
Deutsche Telekom is one of the world's leading integrated telecommunications companies, with more than 261 million mobile customers, 25 million fixed-network lines, and 22 million broadband customers. For more information, visit the Deutsche Telekom corporate information homepage.

About T.Capital
T.Capital manages over €2.3 billion in assets on behalf of Deutsche Telekom across both Venture Capital and Growth/Buyout. The VC team makes initial investments of €1–15 million in Series A to C rounds across the US, Europe, and Israel. While industry- and business model-agnostic, the firm focuses on themes such as AI & cloud infrastructure, security, consumer, and connectivity. By backing ambitious founders, T.Capital provides access to Deutsche Telekom’s infrastructure, joint go-to-market opportunities, commercial resources, and global network. Recent investments — alongside Decagon — include n8n (workflow automation), 11Labs (voice synthesis and speech AI), Perplexity (AI-native search), or Airalo (global eSIM marketplace).

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110484211/en/

Contacts

MEDIA CONTACTS
Decagon: Emilie Cole emilie.cole@decagon.ai
Deutsche Telekom: Verena Fulde verena.fulde@telekom.de
T.Capital: Karine Peters karine.peters@dtcp.capital
Please reach out to all contacts in correspondence.

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye